samedan logo
 
 
 
spacer
home > ebr > summer 2019 > the factory for next- generation therapies
PUBLICATIONS
European Biopharmaceutical Review

The Factory for Next- Generation Therapies

This edition of European Biopharmaceutical Review features articles that support the current momentum of discovery and development in a number of advanced cell and medicinal therapy areas. Unarguably, this is where medicine is headed. In terms of the latest advancements in cell-based therapies and cancer, we can now extract, reprogramme, expand, and reintroduce a patients’ own ‘supercharged’ T cells to fight B cell lymphoblastic leukaemia and B cell non-Hodgkin’s lymphoma through chimeric antigen receptor (CAR) T cell therapy. Could we have imagined this progress, or even the entire field of immunoncology, as it now stands 30 years ago?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera joins IPAC-RS as an Associate Member

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Nemera’s decision to join IPAC-RS is part of its commitment to advance science and innovation. Nemera is committed to enhancing better patient outcomes by seeking innovative solutions and contributing actively to discussions about the future of drug delivery devices. Its membership in IPAC-RS will facilitate this important commitment.
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement